X

Trial Profile

A Clinical Trial of the Absorption, Metabolism and Excretion of [14C]SHR0302 in Healthy Chinese Adult Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivarmacitinib (Primary)
Indications Alopecia areata; Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus; Ulcerative colitis; Vitiligo
Focus Pharmacokinetics
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

30 Jun 2022 Status changed from active, no longer recruiting to completed.
16 Nov 2021 Planned End Date changed from 30 Sep 2021 to 31 Dec 2021.
16 Nov 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com